Skip to main content
Contact Us
Subscribe
E-Edition
84°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Enveric Biosciences Inc
(NQ:
ENVB
)
0.4703
-0.0007 (-0.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Enveric Biosciences Inc
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
September 21, 2023
Via
Benzinga
Enveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Here
September 21, 2023
The U.S. Patent and Trademark Office (USPTO) has issued a new patent granting IP rights for the novel composition of matter and methods of use on the psilocybin-based molecules series EVM301 to its...
Via
Benzinga
Topics
Derivatives
Intellectual Property
Exposures
Derivatives
Intellectual Property
Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates
September 20, 2023
From
Enveric Biosciences
Via
Business Wire
Porch Group And 2 Other Stocks Under $3 Insiders Are Buying
September 20, 2023
The Dow Jones closed lower by over 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
September 18, 2023
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next
Via
Benzinga
Exposures
Product Safety
Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023
September 18, 2023
From
Enveric Biosciences
Via
Business Wire
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
September 11, 2023
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives
September 11, 2023
From
Enveric Biosciences
Via
Business Wire
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
September 05, 2023
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Via
Benzinga
Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives
September 05, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference
August 30, 2023
From
Enveric Biosciences
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 29, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
August 29, 2023
It's time for another dive into the biggest pre-market stock movers as we check out the shares worth watching on Tuesday!
Via
InvestorPlace
Boosting Next-Gen Mental Health Care: Enveric's New US Patent For Anxiety Treatment
August 28, 2023
The USPTO issued a patent covering Enveric Biosciences’ (NASDAQ: ENVB) lead candidate EB-373, a psilocin prodrug under development for the treatment of anxiety disorder.
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
August 28, 2023
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials
Via
Benzinga
Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs
August 28, 2023
From
Enveric Biosciences
Via
Business Wire
Marijuana Stock Movers For August 23, 2023
August 23, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Cannabis Stock Gainers And Losers From August 24, 2023
August 24, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
August 21, 2023
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds
Via
Benzinga
Topics
Cannabis
Economy
Exposures
Cannabis
Interest Rates
Marijuana Stock Movers For August 22, 2023
August 22, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Enveric Completes Manufacturing Of Its Psilocin Prodrug To Supply Drug Material For Completion Of Preclinical Program
August 21, 2023
Enveric Biosciences (NASDAQ: ENVB) has completed manufacturing of drug material enabling the completion of preclinical work for EB-373 including all bioanalytical method validation, GLP toxicology and...
Via
Benzinga
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program
August 21, 2023
From
Enveric Biosciences
Via
Business Wire
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023
August 21, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Enveric's Q2 2023 Financials Show Immediate Need For Budget-Slimming Toward A Clinical-Staged 2024
August 14, 2023
Next-gen psychedelics business Enveric Biosciences (NASDAQ: ENVB) reported its unaudited financial results for the second quarter of 2023 ended June 30. Results show:
Via
Benzinga
Cannabis Stock Gainers And Losers From August 16, 2023
August 16, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
August 14, 2023
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published
Via
Benzinga
Marijuana Stock Movers For August 15, 2023
August 15, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results
August 14, 2023
From
Enveric Biosciences, Inc.
Via
Business Wire
Cannabis Stock Gainers And Losers From August 11, 2023
August 11, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 08, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.